Lonza shares rise 6.7% after CHI exit announcement Company to focus on CDMO business restructuring Plans M&A for tech and capacity opportunities Dec 12 (Reuters) - Swiss contract drugmaker Lonza (LONN ...
This contract was a sole-source acquisition. Fiscal year 2025 research, development, test and evaluation funds in the amount of $4,972 are being obligated at the time of award. The Space Systems ...
This option is part of Emergent’s existing 10-year contract with BARDA for advanced development and procurement of Ebanga™, with a maximum value of $704 million Program progress and performance ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback